It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRA’s FA Score shows that 0 FA rating(s) are green whileNVCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRA’s TA Score shows that 6 TA indicator(s) are bullish while NVCR’s TA Score has 6 bullish TA indicator(s).
BMRA (@Medical Specialties) experienced а +5.68% price change this week, while NVCR (@Medical Specialties) price change was +0.24% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.94%. For the same industry, the average monthly price growth was +13.34%, and the average quarterly price growth was +704.34%.
BMRA is expected to report earnings on Jan 16, 2024.
NVCR is expected to report earnings on Feb 22, 2024.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
|BMRA||NVCR||BMRA / NVCR|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMRA's Valuation (35) in the Medical Specialties industry is somewhat better than the same rating for NVCR (100). This means that BMRA’s stock grew somewhat faster than NVCR’s over the last 12 months.
BMRA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVCR (100). This means that BMRA’s stock grew similarly to NVCR’s over the last 12 months.
BMRA's SMR Rating (97) in the Medical Specialties industry is in the same range as NVCR (97). This means that BMRA’s stock grew similarly to NVCR’s over the last 12 months.
BMRA's Price Growth Rating (87) in the Medical Specialties industry is in the same range as NVCR (94). This means that BMRA’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's P/E Growth Rating (9) in the Medical Specialties industry is significantly better than the same rating for BMRA (100). This means that NVCR’s stock grew significantly faster than BMRA’s over the last 12 months.
5 days ago90%
4 days ago74%
4 days ago85%
4 days ago78%
4 days ago73%
4 days ago76%
4 days ago89%
4 days ago73%
4 days ago80%
4 days ago77%
4 days ago82%
4 days ago85%
5 days ago78%
6 days ago77%
13 days ago82%
19 days ago85%
8 days ago82%
4 days ago69%
4 days ago86%
4 days ago87%
A.I.dvisor tells us that BMRA and NVCR have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BMRA and NVCR's prices will move in lockstep.
A.I.dvisor tells us that NVCR and NVRO have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVCR and NVRO's prices will move in lockstep.